Showing 2671-2680 of 3246 results for "".
- FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Formhttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-idp-121-acne-treatment-in-lotion-form/2457925/The FDA has accepted Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.
- Med Spas on Fleek with Millennialshttps://practicaldermatology.com/news/med-spas-on-fleek-with-millennials/2457940/Younger generations are driving the med spa boom, according to a new American Med Spa Association (AmSpa) study. The medical spa industry is one of the fastest developing in the US, with revenues growing at a double-digit pace since 2010, and by more than 20 percent each year since 2013.
- SK Breakthrough: FDA Approves Eskata (hydrogen peroxide) Topical Solution from Aclarishttps://practicaldermatology.com/news/sk-breakthrough-fda-approves-eskata-hydrogen-peroxide-topical-solution-from-aclaris/2457950/The FDA has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) from Aclaris Therapeutics, Inc. for the treatment of seborrheic keratoses (SKs). SKs are non-cancerous skin growths that affect more than 83 million American adults. They may frequently appear in highly visible are
- Almirall and Athenex Form Strategic Partnership for Treatment of AKshttps://practicaldermatology.com/news/almirall-and-athenex-form-strategic-partnership-for-treatment-of-aks/2457957/Almirall, S.A and Athenex, Inc. recently formed a partnership to further develop and commercialize KX2-391 for the treatment of actinic keratosis (AK) and other skin conditions. Subject to the terms and conditions of the license agreement, Athenex will grant to Almirall an exclusive
- Revance: RT002 Achieves 6-Month Duration in Phase 3https://practicaldermatology.com/news/revance-rt002-achieves-6-month-duration-in-phase-3/2457959/Revance Therapeutics’ next-generation neuromodulator DaxibotulinumtoxinA for Injection (RT002) delivered positive top-line results in alleviating moderate-to-severe glabellar lines in two pivotal SAKURA Phase 3 trials with duraction of effect up to 6 months. RT002 appeared ge
- Milestone Scientific Set To Launch New Botox Delivery Instrumenthttps://practicaldermatology.com/news/milestone-scientific-set-to-launch-new-botox-delivery-instrument/2457965/Botulinum toxin injections may be about to get smarter and more comfortable as Milestone Scientific Inc. gears up to launch its novel and proprietary cosmetic injection instrument. The new cosmetic injection instrument allows the clinician
- Water Baths As Effective As Bleach Baths for Eczemahttps://practicaldermatology.com/news/water-baths-as-effective-as-bleach-baths-for-eczema/2457967/Water baths are as good as bleach baths for treating eczema, and they are safer, finds a new Northwestern Medicine study. Bleach baths can cause stinging and burning of skin, and occasionally even trigger asthma flare-ups in patients. “I don’t know if it throws the bab
- Research: Adequate Sleep May Speed Wound Healinghttps://practicaldermatology.com/news/research-adequate-sleep-may-speed-wound-healing/2457969/Getting more sleep may help wound healing, and a nutrition supplement can also add some benefit, according to a new study in the Journal of Applied Physiology. Physical and emotional str
- Isdin Introduces Two New Productshttps://practicaldermatology.com/news/isdin-introduces-two-new-products/2457977/ISDIN is rolling out ISDIN Age Contour plus a new shade in their ISDINCEUTICS Skin Drops collection. ISDIN AGE CONTOUR is a triple-action face and neck cream that aims to reduce jawline sagging and glycation in the skin as well as protect&nb
- Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitorshttps://practicaldermatology.com/news/long-term-use-of-lillys-taltz-shows-efficacy-improvements-in-psa-for-patients-with-prior-inadequate-response-or-intolerance-to-tnf-inhibitors/2457980/Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 weeks, according to Eli Lilly and Company. Interi